AU761206B2 - Methods of downmodulating the immune response to therapeutic proteins - Google Patents

Methods of downmodulating the immune response to therapeutic proteins Download PDF

Info

Publication number
AU761206B2
AU761206B2 AU60578/99A AU6057899A AU761206B2 AU 761206 B2 AU761206 B2 AU 761206B2 AU 60578/99 A AU60578/99 A AU 60578/99A AU 6057899 A AU6057899 A AU 6057899A AU 761206 B2 AU761206 B2 AU 761206B2
Authority
AU
Australia
Prior art keywords
agent
antibody
factor viii
cell
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU60578/99A
Other languages
English (en)
Other versions
AU6057899A (en
Inventor
Mary Collins
Gary S. Gray
Leon W. Hoyer
Jiahua Qian
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
American National Red Cross
Genetics Institute LLC
Original Assignee
American National Red Cross
Genetics Institute LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American National Red Cross, Genetics Institute LLC filed Critical American National Red Cross
Publication of AU6057899A publication Critical patent/AU6057899A/en
Assigned to GENETICS INSTITUTE, LLC, AMERICAN RED CROSS reassignment GENETICS INSTITUTE, LLC Change of Name of Applicant under S 104 Assignors: AMERICAN RED CROSS, GENETICS INSTITUTE INC.
Application granted granted Critical
Publication of AU761206B2 publication Critical patent/AU761206B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU60578/99A 1998-09-21 1999-09-21 Methods of downmodulating the immune response to therapeutic proteins Ceased AU761206B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15817898A 1998-09-21 1998-09-21
US09/158178 1998-09-21
PCT/US1999/021991 WO2000016801A1 (en) 1998-09-21 1999-09-21 Methods of downmodulating the immune response to therapeutic proteins

Publications (2)

Publication Number Publication Date
AU6057899A AU6057899A (en) 2000-04-10
AU761206B2 true AU761206B2 (en) 2003-05-29

Family

ID=22566971

Family Applications (1)

Application Number Title Priority Date Filing Date
AU60578/99A Ceased AU761206B2 (en) 1998-09-21 1999-09-21 Methods of downmodulating the immune response to therapeutic proteins

Country Status (21)

Country Link
EP (1) EP1115423A1 (no)
JP (1) JP2002526455A (no)
KR (1) KR20010085830A (no)
CN (1) CN1331602A (no)
AU (1) AU761206B2 (no)
BR (1) BR9913991A (no)
CA (1) CA2343916A1 (no)
CZ (1) CZ20011021A3 (no)
EA (1) EA005236B1 (no)
HK (1) HK1039059A1 (no)
HU (1) HUP0103960A3 (no)
IL (1) IL142069A0 (no)
LT (1) LT4920B (no)
LV (1) LV12768B (no)
MX (1) MXPA01002898A (no)
NO (1) NO20011412L (no)
NZ (1) NZ511034A (no)
PL (1) PL346796A1 (no)
SI (1) SI20626A (no)
WO (1) WO2000016801A1 (no)
ZA (1) ZA200103156B (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
EP1289552B1 (en) * 2000-05-19 2006-03-29 The Center for Blood Research, INC. Methods for treating hemostatic disorders by soluble p-selectin
EP1636579A4 (en) * 2003-06-10 2011-10-05 Smiths Detection Inc SENSOR ASSEMBLY
GB201508024D0 (en) 2015-05-11 2015-06-24 Haemostatix Ltd Haemostatic compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996012406A1 (en) * 1994-10-19 1996-05-02 Genetic Therapy, Inc. Gene therapy involving concurrent and repeated administration of adenoviruses and immunosuppressive agents
AU8153698A (en) * 1997-06-20 1999-01-04 Biogen Idec Ma Inc. Cd154 blockade therapy for therapeutic protein inhibitor syndrome

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5171569A (en) 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
CA1341174C (en) 1985-04-12 2001-01-30 John J. Toole Jr. Procoagulant proteins derived from factor viii: c
US5422260A (en) 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
FR2657884B1 (fr) 1990-02-05 1994-09-02 Tm Innovation Procede pour la preparation du facteur viii humain et d'analogues du facteur viii.
US5661008A (en) 1991-03-15 1997-08-26 Kabi Pharmacia Ab Recombinant human factor VIII derivatives
US5770197A (en) 1991-06-27 1998-06-23 Bristol-Myers Squibb Company Methods for regulating the immune response using B7 binding molecules and IL4-binding molecules
DE69226871T3 (de) 1991-06-27 2009-09-24 Bristol-Myers Squibb Co. CTL4A-Rezeptor, ihn enthaltenden Fusionsproteine und deren Verwendung
WO1993009804A1 (en) 1991-11-18 1993-05-27 The Scripps Research Institute Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation
US5663060A (en) 1992-04-07 1997-09-02 Emory University Hybrid human/animal factor VIII
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5744446A (en) 1992-04-07 1998-04-28 Emory University Hybrid human/animal factor VIII
US5621039A (en) 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
WO1996005860A1 (en) * 1994-08-19 1996-02-29 Novo Nordisk A/S A method of treating a patient with a biologically active compound
US5714583A (en) 1995-06-07 1998-02-03 Genetics Institute, Inc. Factor IX purification methods
AU710998B2 (en) * 1996-03-20 1999-10-07 Bristol-Myers Squibb Company Methods for inhibiting an immune response by blocking the GP39/CD40 and CTLA4 /CD28/B7 pathways and compositions for use therewith
DE69837322T2 (de) * 1997-01-10 2007-11-22 Biogen Idec Ma Inc., Cambridge Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln
US8112896B2 (en) 2009-11-06 2012-02-14 Hexagon Metrology Ab Articulated arm

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996012406A1 (en) * 1994-10-19 1996-05-02 Genetic Therapy, Inc. Gene therapy involving concurrent and repeated administration of adenoviruses and immunosuppressive agents
AU8153698A (en) * 1997-06-20 1999-01-04 Biogen Idec Ma Inc. Cd154 blockade therapy for therapeutic protein inhibitor syndrome

Also Published As

Publication number Publication date
LT4920B (lt) 2002-06-25
BR9913991A (pt) 2001-07-03
IL142069A0 (en) 2002-03-10
NZ511034A (en) 2004-03-26
HUP0103960A2 (hu) 2002-02-28
WO2000016801A9 (en) 2000-10-26
AU6057899A (en) 2000-04-10
WO2000016801A1 (en) 2000-03-30
LT2001045A (en) 2002-01-25
MXPA01002898A (es) 2002-06-04
CA2343916A1 (en) 2000-03-30
HUP0103960A3 (en) 2003-09-29
EA200100385A1 (ru) 2001-10-22
HK1039059A1 (zh) 2002-04-12
LV12768A (en) 2001-12-20
KR20010085830A (ko) 2001-09-07
LV12768B (lv) 2002-06-20
CZ20011021A3 (cs) 2001-10-17
JP2002526455A (ja) 2002-08-20
SI20626A (sl) 2002-02-28
PL346796A1 (en) 2002-02-25
EA005236B1 (ru) 2004-12-30
NO20011412D0 (no) 2001-03-20
CN1331602A (zh) 2002-01-16
ZA200103156B (en) 2002-07-18
EP1115423A1 (en) 2001-07-18
NO20011412L (no) 2001-05-16

Similar Documents

Publication Publication Date Title
Qian et al. Prevention and treatment of factor VIII inhibitors in murine hemophilia A
Lollar Pathogenic antibodies to coagulation factors. Part one: factor VIII and factor IX
JP4052524B2 (ja) Ｔ細胞における抗原特異性アポトーシスの誘導のためのリガンド
AU709711B2 (en) Methods for modulating T cell unresponsiveness
US20120269806A1 (en) Methods of inducing tolerance
US20080095774A1 (en) Agents and Methods for Specifically Blocking CD28-Mediated Signaling
US20210340214A1 (en) Cd80 extracellular domain fc fusion protein dosing regimens
BG64436B1 (en) Cd154 blockade therapy for the treatment of protein inhibition syndrome
US20210355231A1 (en) Treatment and prevention of hemophilic arthropathy with an antibody against endothelial cell protein c receptor (epcr)
AU761206B2 (en) Methods of downmodulating the immune response to therapeutic proteins
US20070092506A1 (en) Use of rapamycin and agents that inhibit B7 activity in immunomodulation
Fijnvandraat et al. Immunobiology of inhibitor development in hemophilia A
US20030161827A1 (en) Therapies that improve graft survival
WO2021173903A1 (en) Cd80 extracellular domain fc fusion protein therapy
US20230023174A1 (en) Cd80 extracellular domain fc fusion protein regimens
Martín-Salces Hemophilia A: New Drugs
US20020071839A1 (en) Use of a combination of agents that modulate B7 activity in inhibiting intestinal allograft rejection
Bril Factor VIII inhibitors in mild haemophilia A
Chen et al. Immunological tolerance of human hepatocyte xenograft induced by adenovirus vector-mediated CTLA4Ig gene transfer
Miao et al. Immunomodulation of transgene responses following naked DNA transfer
AU3437902A (en) Methods for modulating T cell unresponsiveness
AU3794299A (en) Methods for modulating T cell unresponsiveness

Legal Events

Date Code Title Description
TC Change of applicant's name (sec. 104)

Owner name: GENETICS INSTITUTE, LLC, AMERICAN RED CROSS

Free format text: FORMER NAME: GENETICS INSTITUTE, INC., AMERICAN RED CROSS

FGA Letters patent sealed or granted (standard patent)